Guildford, United Kingdom
Guildford, United Kingdom

Time filter

Source Type

Muscogiuri G.,Futura Medical | Colao A.,University of Naples Federico II
Archives of Toxicology | Year: 2016

Phtalates are commonly found in several household products such as food packaging, furniture and toys. Humans are exposed to phtalates through different ways such as inhalation, ingestion and dermal contact. Due to the abundance of plastic in our society, the exposure to phtalates is ubiquitous. A growing body of evidence investigated the association of phtalate exposure with cardiovascular risk factors, i.e., obesity, type 2 diabetes and hypertension. Phtalates are thought to contribute to obesity through their binding and activation of PPARγ receptor that in turn results in the upregulation of adipocyte production. Phtalates are also known to interfere with insulin signaling and to increase oxidative stress. All these mechanisms contribute to the onset of insulin resistance. Recent evidences support a role of phtalates in the pathogenesis of atherosclerosis and hypertension. Thus, the aim of this communication was to summarize the current evidences dealing with the association of phtalates and cardiovascular risk factors. © 2016 Springer-Verlag Berlin Heidelberg


Auriemma R.S.,Futura Medical | Pivonello R.,University of Naples Federico II | Ferreri L.,University of Naples Federico II | Priscitelli P.,Futura Medical | Colao A.,University of Naples Federico II
Endocrinology and Metabolism Clinics of North America | Year: 2015

Cabergoline (CAB) is widely used for the medical treatment of pituitary tumors, particularly those associated with hormone hypersecretion. Whether treatment with CAB is associated with an increased risk of clinically relevant cardiac valve disease in patients with pituitary tumors is still debated. In most studies, CAB has been found not associated with an increased risk of significant valvulopathy, and no correlation has been shown between valvular abnormalities and CAB duration or cumulative dose. This review provides an overview of the studies reporting on the outcome of CAB in terms of cardiac valve disease in patients with pituitary tumors. © 2015 Elsevier Inc.


Brunner M.,Medical University of Vienna | Davies D.,Futura Medical | Martin W.,Pharmakin GmbH | Leuratti C.,Cross S.A. | And 2 more authors.
British Journal of Clinical Pharmacology | Year: 2011

AIMS: To evaluate the relative plasma and tissue availability of diclofenac after repeated topical administration of a novel diclofenac acid-based delivery system under development (DCF100C). METHODS: This was a single-centre, open-label, three-period, crossover clinical trial of five discrete diclofenac formulations. Test preparations comprised two concentrations (1.0% and 2.5%) of DCF100C, with and without menthol and eucalyptus oil (total daily doses of 5mg and 12.5mg). Voltaren® Emulgel® gel (1.0%) was the commercially available comparator (total daily dose of 40mg). Topical application was performed onto the thigh of 20 male healthy subjects for 3 days. Applying a Youden square design, each drug was evaluated in 12 subjects, with each subject receiving three test preparations. Blood sampling and in vivo microdialysis in subcutaneous adipose and skeletal muscle tissues were performed for 10h after additional final doses on the morning of day 4. RESULTS: All four DCF100C formulations demonstrated a three- to fivefold, dose-dependent increase in systemic diclofenac availability compared with Voltaren® Emulgel® and were approximately 30-40 times more effective at facilitating diclofenac penetration through the skin, taking different dose levels into account. Tissue concentrations were low and highly variable. The 2.5% DCF100C formulation without sensory excipients reached the highest tissue concentrations. AUC(0,10h) was 2.71 times greater than for Voltaren® Emulgel® (90% CI 99.27, 737.46%). Mild erythema at the application site was the most frequent adverse event associated with DCF100C. There were no local symptoms after treatment with the reference formulation. CONCLUSION: DCF100C formulations were safe and facilitated greater diclofenac penetration through the skin compared with the commercial comparator. DCF100C represents a promising alternative to oral and topical diclofenac treatments that warrants further development. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.


Patent
Futura Medical | Date: 2010-11-10

A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.


Patent
Futura Medical | Date: 2014-11-27

There is provided a topical pharmaceutical composition comprising the following components and percentages: ester of salicylic or nicotinic acid10-20%; menthol5-10%; lower alcohol15-35%; water10-20%; propylene glycol and/or pentane-1,5-diol15-35%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol2-16%; and, optionally, up to 5% camphor, all percentages being by weight. Also provided is a topical pharmaceutical composition comprising a volatile phase and a non-volatile phase, the non-volatile phase comprising from 32-81% of the total composition by weight, and comprising the following non-volatile constituents, expressed as % weight of the non-volatile phase: ester of salicylic or nicotinic acid14-48%; menthol7-27%; propylene glycol and/or pentane-1,5-diol25-67%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol3-35%, and a concentrate comprising the non-volatile components of this composition. The compositions are useful in the treatment or prevention of pain.


Patent
Futura Medical | Date: 2014-03-04

There is provided a condom having a coating or deposit of a composition which includes a physiologically-active agent such as glyceryl trinitrate, wherein the condom has been treated with a neutralising or acidic material such that the condom, when immersed in water, results in the water having a pH of 7 or less. The condom may be treated with an acidic slurry of dusting powder. Also provided is a process for the manufacture of condoms, in which the process includes the steps of: 1) treating the formed condoms with a neutralising or acidic material; and 2) thereafter applying to the condoms a composition including a physiologically-active agent such as glyceryl trinitrate, wherein the condoms, when immersed in water, results in the water having a pH of 7 or less.


Trademark
Futura Medical | Date: 2012-04-24

Pharmaceutical and medical preparations and substances, namely, pharmaceutical preparations for topical application to the skin in order to promote the absorption of active molecules through the skin for use in medical treatment to effect sexual wellbeing and pain relief; transdermal delivery systems for medical purposes or for use in health care comprising a transport substrate and an active ingredient and transdermal delivery systems comprising a patchless lotion including an active ingredient for therapeutic or medical purposes for use in the treatment of adverse medical conditions and distributed by medical personnel and/or pharmacists.


Trademark
Futura Medical | Date: 2015-12-08

Contraceptive apparatus; condoms.


Futura Medical has developed a "new generation" of topical pain relief with two products that target more active ingredients directly to the point of pain. The new products have the potential to transform the pain relief market, according to chief executive James Barder. Both products - TPR100 Diclofenac gel and TIB200 Ibuprofen gel - benefit from Futura's innovative multi-action skin permeation technology, DermaSys®, which offers deeper and more targeted pain relief for up to 12 hours. Earlier studies have shown up to twenty times greater drug penetration through the skin than existing market leading brands. A recent in-vivo clinical trial strongly supported these findings, delivering statistically significant efficacy in pain relief. Barder is convinced that brands need to exploit state-of-the-art delivery technologies in order to maintain market share. "Oral use of painkillers has come under scrutiny, and consumers and health professionals will be looking for alternatives. Current topical pain relief is often ineffective compared to its oral counterparts. Add to this increased concerns over the long term usage of systemic medication and it's evident that what's needed is a new generation of topical pain relief." Professor Andrew Moore, Director of Pain Research at Nuffield Centre of Anaesthetics, University of Oxford, agrees that existing analgesics often fall short of the mark. "The aim of treating pain is to provide good levels of pain relief, quickly, to as many people as possible. In recent years we have recognised that treatments fail to achieve these aims for a good proportion of people treated." The global OTC topical pain relief market for 2015 is estimated to be US$ 5 billion (Nicholas Hall 2011 indexed to 2015 estimated). Barder is confident that growth will accelerate over the next decade due to the increased incidence of obesity, an ageing population and increased incidence of osteoarthritis. Osteoarthritis affects 8.75 million people in Britain, a third of the population over the age of 45, with osteoarthritis of the knee affecting 18% of the British population. With UK Medical Research Council predicting that life expectancy will reach 90 by 2030, an ageing population will boost this figure further. "New formulations of oral and topical analgesics have begun to make a real difference, and this has arguably been more important than new pain relief compounds," says Professor Moore. "New generations of pain relief will contribute to improving the lot of people with pain." Futura Medical is already in discussion with partners, including leading brands and generics, to commercialise both products. Based in Surrey, UK, Futura's development pipeline focuses on pain relief management and sexual healthcare. Futura Medical is gaining recognition within the pharmaceutical industry for its expertise in transdermal drug delivery technology. For further information please contact: Bethia Stone at Satellite PR +44-20-7702-6546 bethia@satellitepr.com

Loading Futura Medical collaborators
Loading Futura Medical collaborators